Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation

Area of Science:

• Biomedical innovation and pharmaceutical R&D.

Background:

• Pharmaceutical research and development (R&D) productivity has not seen broad improvement despite rapid biomedical advancements.
• Companies face pressure to adapt to market and scientific changes, necessitating new product development and commercialization strategies.
• There is a growing trend for firms to leverage external innovation, including federal R&D investments, talent, and infrastructure.

Purpose of the Study:

• To examine the transition towards external innovation in the pharmaceutical industry.
• To illustrate the effectiveness of collaborative, externally funded research initiatives.

Main Methods:

• The Sanofi-MIT Partnership provided seed funding to MIT investigators for novel solution development.
• Projects involved highly collaborative efforts with bidirectional information and material exchange.
• Awards featured relatively small funding amounts and short time frames to ensure flexibility.

Main Results:

• The partnership facilitated the development of novel solutions and approaches in areas relevant to Sanofi.
• The collaborative model enabled adaptable and flexible advancement of translational science.
• This approach demonstrated a viable model for external innovation in the pharmaceutical sector.

Conclusions:

• External innovation models, exemplified by the Sanofi-MIT Partnership, are crucial for overcoming stagnant R&D productivity.
• Collaborative, flexible, and externally funded initiatives can effectively advance translational science.
• The pharmaceutical industry must embrace such transitions to maintain competitiveness and drive innovation.